Skip to content
sellWeak cluster of 3

Jacob Chacko sold $302k of ORIC

PRESIDENT AND CEO at Oric Pharmaceuticals, Inc.. 33,374 shares at an average of $9.06, traded Dec 16, 2025, filed Dec 17, 2025.

Warning score
39
Value
$302k
33,374 shares
Holdings after
581,711
-5% from before
From 52-week low
+114%
low $4.26, close $9.12
From 52-week high
-37%
high $14.41, as of Dec 16, 2025

Score components

  • Role
    CEO
    +25
  • Trade size
    $302k at market
    +14
  • Share of holdings sold
    Sold 5.4% of holdings
    0
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ORICOct 9, 2026 · close 11.99
Since filing Dec 17, 2025: +45.9%SPY +17.2% · excess +28.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001608936-25-000014, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 15, 2025MOption exercise
Common Stock
+83,666$0.00$0615,085Dec 17, 2025
Dec 16, 2025SOpen-market sale
Common Stock
-33,374$9.06$302k581,711Dec 17, 2025
Dec 15, 2025MOption exercise
Restricted Stock Unitderivative
-22,000$0.00$00Dec 17, 2025
Dec 15, 2025MOption exercise
Restricted Stock Unitderivative
-28,333$0.00$028,334Dec 17, 2025
Dec 15, 2025MOption exercise
Restricted Stock Unitderivative
-33,333$0.00$066,667Dec 17, 2025

Related signals

Other insiders at Oric Pharmaceuticals, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
2Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Richard A. Heyman
director
$87k
6,700 shares
-16%
12Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Dominic Piscitelli
Chief Financial Officer
$181k
13,400 shares
-16%
0Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Dominic Piscitelli
Chief Financial Officer
$8,103
600 shares
-1%
30Weak
ORICsell 3
Oric Pharmaceuticals, Inc.
Pratik S Multani
Chief Medical Officer
$97k
10,720 shares
-14%
37Weak
ORICsell 3
Oric Pharmaceuticals, Inc.
Dominic Piscitelli
Chief Financial Officer
$97k
10,720 shares
-14%
30Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Jacob Chacko
PRESIDENT AND CEO
$462k
37,461 shares
-7%
11Weak
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Dominic Piscitelli
Chief Financial Officer
$160k
11,000 shares
-19%
43Moderate
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Jacob Chacko
PRESIDENT AND CEO
$1.1M
87,539 shares
-13%
43Moderate
ORICsell 210b5-1
Oric Pharmaceuticals, Inc.
Jacob Chacko
PRESIDENT AND CEO
$1.3M
125,000 shares
-16%
24Weak
ORICsell10b5-1
Oric Pharmaceuticals, Inc.
Dominic Piscitelli
Chief Financial Officer
$201k
20,000 shares
-29%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Jacob Chacko sold $302k of ORIC | InsiderTell